VitaSpring Biomedical Income Statement

Financials in millions USD. Fiscal year is February - January.

Millions USD. Fiscal year is Feb - Jan.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan '25 Jan 31, 2025	Jan '24 Jan 31, 2024	Jan '23 Jan 31, 2023	Jan '22 Jan 31, 2022	Jan '21 Jan 31, 2021
Revenue	-	-	-	5.61	0.25
Revenue Growth (YoY)	-	-	-	2161.56%	1539.37%
Cost of Revenue	-	-	3.33	3.55	0.14
Gross Profit	-	-	-3.33	2.07	0.11
Selling, General & Admin	0.67	1.09	0.84	0.94	0.54
Other Operating Expenses	-	-	-	-	0
Operating Expenses	0.68	1.11	0.84	0.94	0.54
Operating Income	-0.68	-1.11	-4.18	1.13	-0.42
Other Non Operating Income (Expenses)	-	-	-	-	-0
EBT Excluding Unusual Items	-0.68	-1.11	-4.18	1.13	-0.43
Asset Writedown	-	-0.01	-	-	-
Other Unusual Items	-	-	0.01	-	-
Pretax Income	-0.68	-1.12	-4.17	1.13	-0.43
Income Tax Expense	0.1	-	-0.01	0.22	-
Net Income	-0.77	-1.12	-4.16	0.91	-0.43
Net Income to Common	-0.77	-1.12	-4.16	0.91	-0.43
Shares Outstanding (Basic)	207	207	207	206	91
Shares Outstanding (Diluted)	207	207	207	206	91
Shares Change (YoY)	-	0.25%	0.26%	126.13%	67.11%
EPS (Basic)	-0.00	-0.01	-0.02	0.00	-0.00
EPS (Diluted)	-0.00	-0.01	-0.02	0.00	-0.00
Free Cash Flow	-0.01	-0.03	-0.08	-0.34	-0.04
Free Cash Flow Per Share	-	-	-	-0.00	-
Gross Margin	-	-	-	36.84%	45.20%
Operating Margin	-	-	-	20.07%	-171.12%
Profit Margin	-	-	-	16.20%	-171.39%
Free Cash Flow Margin	-	-	-	-6.10%	-16.97%
EBITDA	-0.67	-1.09	-4.16	1.14	-0.42
EBITDA Margin	-	-	-	20.22%	-170.94%
D&A For EBITDA	0.01	0.02	0.02	0.01	0
EBIT	-0.68	-1.11	-4.18	1.13	-0.42
EBIT Margin	-	-	-	20.07%	-171.12%
Effective Tax Rate	-	-	-	19.27%	-